DELEE

DELEE Aims to Treat Cancer with Blood Test Device Capable of Isolating Tumor Cells. This patent-pending device hopes to advance personalized cancer treatment through a novel approach. DELEE's founding team, with work experience in biomedical engineering, hails from Stanford and Rochester Institute of Technology. The company has successfully conducted a clinical trial in which tumor cells were isolated in 13 out of 15 participants.